Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Combining ciclosporin and simvastatin can cause severe kidney damage.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

PrEP implants are promising for HIV prevention if the number of implants needed is minimized.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Naproxen can cause serious lung issues, but high-dose aspirin might be safer.

Alefacept showed some effectiveness for alopecia areata but needs more research.

Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Some HIV treatments can harm mitochondria, potentially causing side effects like lactic acidosis and nerve damage.

A woman developed severe kidney injury from using simvastatin with ciclosporin, highlighting the need for careful monitoring when combining these drugs.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.

Oral valganciclovir improved a patient's skin condition caused by immunosuppression.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

Zidovudine may cause hair loss in advanced-stage HIV patients.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.